Dr Reddy's launches osteoporosis injection in US

The company's scrip was trading on BSE at Rs 1,888 on Thursday, up 2.8% from previous close

Hyderabad-based pharmaceutical major Dr Reddy’s Laboratories (DRL) has launched zoledronic acid injection in the US market following approval by the United States Food & Drug Administration (USFDA).

The medicine, used to treat osteoporosis in women after menopause, is a therapeutic equivalent generic version of Reclast (zoledronic acid) injection, DRL stated in a press release on Thursday.

The Reclast brand had total US sales of approximately $ 355 million for the most recent twelve months ending February 2013, according to IMS Health.  

DRL's zoledronic acid injection is available in a single use vial for intravenous infusion.

The company's scrip was trading on BSE at Rs 1,888 on Thursday, up 2.9 per cent over the previous close of Rs 1,834.85.